CDK4 and familial pancreatic carcinoma: While preclinical and clinical evidence suggests a potentially favorable impact of CDK4/6 inhibitors on this condition, further investigations are essential in the realm of personalized medicine for individuals with hereditary pancreatic cancer and melanoma.